EBRD homepage
About the EBRD
News & events
Publications
Countries & topics
Projects
 
Project summaries

Approved & signed

Case studies

Environmental documents

Evaluation
Apply for financing
Environment
Capital markets
Working together
 

 

Project summary document

Project name:Pharma Investment B.V.
Country:Regional
Project number:37597
Business sector:General manufacturing
Public/Private:Private
Environmental category:C
Board date:3 December 2007
Status:Signed
Date PSD disclosed:
Date PSD updated:
2 November 2007
Help

Subscribe to PSD
email alerts

Related links
Southeast Europe’s pharmaceuticals sector gets boost from EBRD [Press Release]

Project description
and objectives:

The proposed project will consist of an equity of EUR 15 million to Pharma Investments B.V. The proposed project will support the current operations and future expansion plans of PIBV in the CEE area with the target to create a strong regional pharmaceuticals retail network. PIBV is a subsidiary of Milestone Group Plc, an Icelandic private investment company. The investment programme of EUR 55 million will focus on building a regional pharma network of at least 500 pharmacies with a recognised brand name both through acquisitions and organic growth.

Transition impact:

The main transition impact of the project will derive from the demonstration effect of a successful regional expansion by an experienced foreign investor throughout the CEE countries and the setting of standards of corporate governance and business conduct at the investee company level. In addition, the project will increase competition in the sector through introduction of a wide range of new product choices and additional services, as well as competitive prices to the final customers.

The client:

Pharma Investments B.V., a subsidiary of Milestone Group Plc.

EBRD finance:

EUR 15 million equity.

Total project cost:

EUR 55 million.

Environmental impact:

Screened C/1. The development and operation of retail pharmacy stores and wholesale outlets will have limited environmental, health, safety and labour (EHSL) impacts. The Company's approach to EHSL management has been assessed during due diligence and has been found to be adequate. Provisions covering EHSL due diligence procedures and EU standards will be included in the legal agreements. The Company will be required to provide the Bank with an annual environmental report on EHSL matters

Technical
cooperation:

None.

For consultant opportunities for projects financed by technical cooperation funds, visit procurement of consultants.

Company contact:

Fjolvar Darri Rafnsson, MANAGING DIRECTOR
Pharma Investment B.V.
Drvinje 36
10 000 Zagreb, Croatia

TEL +385 1 3665 093
FAX +385 1 3665 776

E-MAIL: darri@milestone.is

EBRD contact:

Vesna Mukaetova, Operation Leader: mukaetov@ebrd.com

Business opportunities:

For business opportunities or procurement, contact the client company.

General enquiries:

EBRD project enquiries not related to procurement:
Tel: +44 20 7338 7168; Fax: +44 20 7338 7380
Email: projectenquiries@ebrd.com


Project Summary Documents are created before consideration by the EBRD Board of Directors. Details of a project may change following disclosure of a Project Summary Document. Project Summary Documents cannot be considered to represent official EBRD policy.
Terms and conditions Sitemap Feedback